Hookipa restates Gilead deal, gets $35M equity; HIV R&D expanded

HOOKIPA Pharma Inc.

Hookipa assumes additional HIV development responsibility under restated collaboration agreement.
Gilead to purchase up to $35 million of Hookipa common stock to support increased HIV R&D.
Restated agreement covers HBV and HIV vaccine programs using Hookipa's arenavirus technology.
Financial milestones and royalties are redacted but original 2018 deal amended.
Full collaboration agreement filed as Exhibit 10.1 to Form 8-K/A.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.